Abstract: The disclosure relates to novel taxoid-based compositions comprising injectable formulations of these derivatives in the form of an emulsion.
Abstract: The present invention relates to pharmaceutical compositions that act on the p53 protein or its gene and methods of use for the treatment of neurodegenerative diseases.
Type:
Grant
Filed:
August 22, 2007
Date of Patent:
April 30, 2013
Assignee:
Aventis Pharma S.A.
Inventors:
Jacques Mallet, Frederic Revah, Jean-Marie Stutzmann
Abstract: The invention relates to the use of semuloparin or a pharmaceutically acceptable salt thereof for the prevention of a mortality and/or morbidity event, more specifically venous thromboembolism and death, in a patient undergoing major orthopedic surgery, such as hip replacement, knee replacement or hip fracture surgery.
Abstract: The invention relates to the use of semuloparin or a pharmaceutically acceptable salt thereof for the extended prevention of a mortality and/or morbidity event, more specifically venous thromboembolism and death, in a patient having undergone hip fracture surgery.
Abstract: The invention relates to the use of semuloparin or a pharmaceutically acceptable salt thereof as an antithrombotic treatment in patients undergoing hip replacement surgery, wherein said use involves an improved safety in terms of clinically relevant bleedings and of major bleedings compared to a standard antithrombotic treatment.
Abstract: The invention relates to a compound of formula: which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.
Abstract: The invention concerns the production of cholesterol of the Fungi kingdom. More particularly, the invention concerns genetically modified Fungus independently producing cholesterol from a simple carbon source. The invention also concerns the use of the inventive Fungus for producing non-marked and marked cholesterol.
Type:
Application
Filed:
May 24, 2012
Publication date:
November 1, 2012
Applicant:
AVENTIS PHARMA S.A.
Inventors:
Denis POMPON, Bruno DUMAS, Roberto SPAGNOLI
Abstract: The present invention relates to novel compounds and their uses, in particular their pharmaceutical or diagnostic uses or their use as pharmacological targets. More particularly, the present invention relates to a novel protein, referred to as PAP1, as well as to novel peptides and compounds which are capable of modulating, at least partially, the activity of parkin.
Type:
Grant
Filed:
March 28, 2006
Date of Patent:
September 25, 2012
Assignee:
Aventis Pharma S.A.
Inventors:
Han Koutnikova, Alexis Brice, Alain Fournier, Laurent Pradier, Catherine Prades, Isabelle Arnould-Reguigne, Marie-Françoise Rosier-Montus, Olga Corti
Abstract: The invention concerns compositions and methods for preparing recombinant adenoviruses. The resulting adenoviruses can be used for transferring and/or expressing genes in cells, in vitro, ex vivo or in vivo, or also in functional genomics. More particularly, the invention concerns in particular efficient methods for producing adenovirus banks and the use of said banks in functional genomics. The invention also concerns plasmids used for constructing said adenoviruses.
Abstract: The subject of the invention is a method for preparing compounds of general formula (I): in which A, Z, R3 are as defined in the description, and the intermediate compounds for carrying out this method.
Type:
Grant
Filed:
October 29, 2010
Date of Patent:
September 4, 2012
Assignee:
Aventis Pharma S.A.
Inventors:
Denis Prat, Christian Moratille, Francoise Benedetti, Lahlou Nait-Bouda
Abstract: The invention concerns the production of cholesterol in organisms of the Fungi kingdom. More particularly, the invention concerns genetically modified Fungus independently producing cholesterol from a simple carbon source. The invention also concerns the use of the inventive Fungus for producing non-marked and marked cholesterol.
Type:
Grant
Filed:
May 2, 2005
Date of Patent:
July 3, 2012
Assignee:
Aventis Pharma S.A.
Inventors:
Denis Pompon, Bruno Dumas, Roberto Spagnoli
Abstract: A process for the preparation of a composition intended for the oral administration of active principles with unacceptable taste, which comprises from about 15% to about 30% of organoleptically unpleasant active ingredient (principle) that is mixed with from about 60% to about 80% of an ester of glycerol or of a fatty acid, to which a wax is optionally added and to which a surfactant is added, and in that it is prepared by a spray-cooling process which can produce a particle size of less than 350 ?m.
Abstract: The present invention relates to novel yeast strains, methods and genetic constructs for their preparation, and their use for the synthesis or modification of steroidal compounds. More particularly, the invention describes strains having a reduced 20?HSD type activity, in particular by modifying the GCY1 and/or YPR1 genes. The yeast strains of the invention make it possible to improve the efficiency of the synthesis or to increase the selectivity or the yields of the method, as well as the quality of the final product. The strains, methods and compounds of the invention are useful in the search for, the development and the production of products with therapeutic or prophylactic activity, in humans or animals, in particular of steroidal derivatives.
Type:
Grant
Filed:
January 14, 2011
Date of Patent:
May 8, 2012
Assignee:
Aventis Pharma S.A.
Inventors:
Bruno Dumas, Gilles Cauet, Eric Degryse, Tilman Achstetter
Abstract: This invention relates to compounds of formula (I) to processes for the preparation of such compounds, to pharmaceutical compositions comprising such compounds, and to methods of treatment comprising administering of such compounds.
Abstract: The invention concerns nucleic acids coding for mutated or truncated forms of the human parkin gene, or forms comprising multiplication of exons, and the corresponding proteins and antibodies. The invention also concerns methods and kits for identifying mutations of the parkin gene, and for studying compounds for therapeutic purposes.
Type:
Application
Filed:
August 15, 2011
Publication date:
March 15, 2012
Applicants:
INSTITUT NATIONAL SANTE ET RECHERCHE MEDICALE, AVENTIS PHARMA S.A.
Abstract: This invention relates to benzimidazole and benzothiazole compounds of formula (I) to methods of preparing such compounds, pharmaceutical compositions comprising such compounds, and to methods of treatment comprising administering of such compounds.
Abstract: The present invention relates to mixtures of polysaccharides derived from heparin having a mean molecular weight of 1500 to 3000 Daltons and an anti-Xa/anti-IIa ratio greater than 30, their method of preparation and pharmaceutical compositions containing them.
Type:
Grant
Filed:
May 9, 2011
Date of Patent:
December 6, 2011
Assignee:
Aventis Pharma S.A.
Inventors:
Christian Viskov, Vesna Biberovic, Pierre Mourier, Luc Grondard